OncLive® On Air

Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial, considerations for community oncologists when deciding whether to prescribe enfortumab vedotin plus pembrolizumab to patients with urothelial carcinoma, their advice for monitoring and managing treatment-related toxicities with this combination, and more.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Dr Ganjoo discusses unmet needs for patients with malignant PEComa, treatment plan considerations, and the use of nab-sirolimus in this disease.

Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.

Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

Drs Merkow and Connell discuss reasons why they adopted HAI therapy as a treatment offering for patients with CRC, characteristics of patients who are good candidates for this treatment, and more.

Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.

Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.

Drs Graff, Mahtani, McCann, and Rugo shared moments throughout their lives and careers that sparked their interest in oncology, setbacks they overcame when building their careers, obstacles they encounter as women in the field, and ways that gender bias can be confronted at both the individual and institutional levels.

Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting this regulatory decision.

Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

Dr Wagner discusses current unmet needs for patients with PEComa, how ongoing research aims to address some of these gaps, and how findings from the AMPECT trial in particular support the use of nab-sirolimus in patients with advanced malignant disease.

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.

Dr Lunning sits down with Alex Herrera, MD, of City of Hope, to discuss the frontline management of Hodgkin lymphoma, including the rationale for the SWOG 1826 trial, the collaborative efforts between pediatric and adult oncologists that led to the successful initiation of this trial, potential future directions for this research, and more.

Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the potential evolution of NALIRIFOX’s role in the treatment of patients with pancreatic cancer.

Dr Kyriakopoulos sheds light on the potential synergy and pharmacokinetic interactions between masofaniten and enzalutamide when used in combination for patients with prostate cancer; contextualizes safety and pharmacokinetic findings from the phase 1 portion of a phase 1/2 study; and outlines key objectives of the agent’s ongoing evaluation in the phase 2 portion of the study.

Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma, his anticipated use of the agent since its inclusion on UCSF’s formulary, and the debate around Epstein-Barr virus as a selection criteria for treatment eligibility.

Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.

Dr Tripathy discusses aspects of the Miami Breast Cancer Conference that stood out to him during his first time speaking at the meeting, ways that Miami Breast has evolved over the years, and the types of valuable multidisciplinary discussions that the meeting inspires.

Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.

Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer, key efficacy and safety data from the EV-302 trial, and future directions in urothelial cancer research.

Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges related to gender bias that they have faced throughout their careers, growth opportunities that have arisen from these obstacles, and the importance of reflecting on past accomplishments and future goals.

Drs Lunning and Brander discuss the evolution of chronic lymphocytic leukemia management.

Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.

Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated CLL/SLL; key efficacy and safety data from the BRUIN trial; and guidelines for pirtobrutinib use in clinical practice in the CLL/SLL patient population.

Dr Lunning sits down with Kami J. Maddocks, MD, of The Ohio State University Comprehensive Cancer Center––James, to discuss the management of MCL in the up-front setting, including practice-changing findings from the SHINE and TRIANGLE trials; how these trial data have altered the role of first-line BTK inhibitors in chemotherapy-free regimens for patients with MCL; and how patient characteristics, such as age and TP53 mutation status affect up-front treatment feasibility.

Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.

Drs Monk and Tarantino highlight current research investigating B7-H4–directed ADCs in multiple solid tumor types; other promising ADCs in development for gynecologic cancers; and future research needed to clarify unanswered questions regarding the sequencing of ADCs in breast cancer.

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new guidance regarding multidisciplinary management.

Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.

Dr Jabbour discusses the activity and the utilization of olverembatinib in chronic myeloid leukemia and expanded upon the role that TKIs can play in the management of malignancies beyond chronic myeloid leukemia and acute lymphoblastic leukemia.

Dr Eskander discusses the impact of social determinants of health on cancer clinical trial participation; effective strategies for considering and engaging diverse communities in the clinical trial process; and how community partnerships can be strengthened to eliminate these financial and logistical barriers.

Dr Lunning and Neha Mehta-Shah, MD, MSCI, of Washington University School of Medicine, highlight challenges that arise when diagnosing patients with PTCL; how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma; and novel frontline agents under investigation in PTCL.

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.

Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.

Dr Abdou discusses how characteristics of patients with breast cancer impact ADC treatment selection and highlights some of the topline takeaways from breast cancer treatment to come out of the 2023 ASCO Annual Meeting.

Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how the addition of toripalimab to the nasopharyngeal carcinoma treatment armamentarium increases the importance of multidisciplinary collaboration.

Dr Lunning sits down with Caron A. Jacobson, MD, MMSc, or Dana-Farber Cancer Institute, to discuss the characteristics of FL that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

Dr Dumbrava discusses the rationale and design of the PYNNACLE trial; phase 1 efficacy and safety findings with PC14586 in patients with p53 Y220C–mutated advanced solid tumors; and the next steps for this research.

Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.

Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on PFS outcomes for patients with pancreatic cancer.

Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care beyond daratumumab, and the importance of confirming earlier post-hoc results from the placebo-controlled phase 3 VITAL trial in the ongoing AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.

Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the CheckMate76K trial, and potential future directions for PD-1 inhibitor–based combinations in the melanoma treatment paradigm.

Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may benefit most from standard chemotherapy vs clinical trial regimens in the frontline setting; and ongoing follicular lymphoma research that may alter the treatment paradigm.

Dr Naumann discusses the role of frontline maintenance therapy for patients with endometrial cancer; which patients are likely to benefit from the RUBY and NRG-GY018 trial regimens; and ongoing research that may elucidate optimal treatments for patients with recurrent, dMMR disease.